SFRP1 and systemic sclerosis: Treatment with the methyltransferase inhibitor 5‐aza attenuates canonical Wnt signaling and alleviates fibrosis in both SSc fibroblasts and a bleomycin‐induced mouse model, underscoring SFRP1's protective role [239].